Type 2 Diabetes Medications That Induce Weight Loss
Mar 22, 2024 · Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. A predominant risk factor for type 2 diabetes is being overweight or obese, so weight loss goals while maintaining normal blood sugar levels are very important for some patients.
History of National Diabetes Month 2024
Oct 30, 2024 · November is National Diabetes Month, dedicated to increasing awareness and education on how diabetes affects the body and how it can be prevented.
Diabetes and Erectile Dysfunction - Endocrinology Advisor
Nov 29, 2024 · Erectile dysfunction is a persistent pattern of being unable to attain and/or maintain a penile erection sufficient for sexual satisfaction. 1 It is a common problem, affecting approximately 30 million men in the United States. 1 Compared to those without diabetes, men with diabetes have an increased risk of developing erectile dysfunction. 2 This article describes how diabetes contributes to ...
SGLT2 Inhibitors - Endocrinology Advisor
Oct 9, 2024 · UGT = UDP-glucuronosyltransferase. From the FDA-approved prescribing information for each medication. 5-9 Warnings and Adverse Reactions. All SGLT2 inhibitors are contraindicated for patients who have hypersensitive reactions to SGLT2 inhibitor treatment. 5-9 Bexagliflozin, canagliflozin, and empagliflozin are not recommended for improving glycemic control in patients with type 2 diabetes who ...
Addison's Disease - Endocrinology Advisor
Apr 2, 2024 · Addison’s disease — also referred to as primary adrenal insufficiency — occurs when the adrenal glands do not produce enough cortisol and/or aldosterone, hormones necessary for regulation of metabolism, blood pressure, immune system functions, the stress response, and other essential physiologic activities. 1 Patients with Addison’s disease experience weakness, fatigue, anorexia ...
How Do GLP-1 Receptor Agonists, Like Ozempic or Mounjaro, Work?
Jun 14, 2024 · Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Glucagon-like peptide-1 (GLP-1) is a hormone released when food is eaten to slow gastric emptying, the process by which food leaves the stomach, so that the body can absorb nutrients from food.
Gastroparesis - Endocrinology Advisor
Oct 29, 2024 · Gastroparesis is a digestive disorder in which patients experience delayed gastric emptying in the absence of any obstruction of gastric outflow. 1 Its characteristic symptoms of nausea, vomiting, bloating, and upper abdominal distention and pain can substantially worsen patients’ quality of life. 1 Gastroparesis commonly develops secondary to diabetes, after surgery, or after exposure to ...
How to Prepare for a Glucose Test - Endocrinology Advisor
Nov 5, 2024 · Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. A glucose test (also called a blood glucose test) is used to determine how much glucose is in your blood. 1 Glucose is a simple form of sugar and the body’s primary source of energy. The results of a glucose test provide information about your overall health and specifically ...
Hypercalcemia - Endocrinology Advisor
Nov 17, 2022 · Hypercalcemia Causes & Presentation. Hypercalcemia is a condition in which the calcium level in your blood is above normal. The normal range of calcium is 8.5 to 10.5 mg/dl (4.3 to 5.3 mEq/L or 2.2 to 2.7 mmol/L). 1 This reference range may differ by 0.5 mg/dl depending on the laboratory or hypercalcemia workup. Patients typically present with symptoms of hypercalcemia when the serum calcium ...
GLP-1 Agonists - Endocrinology Advisor
Oct 8, 2024 · Glucagon-like peptide-1 receptor agonists (GLP-1 agonists) are a newer class of medications that are US Food and Drug Administration (FDA)-approved to manage type 2 diabetes and obesity in conjunction with diet and lifestyle changes. 1 GLP-1 agonists affect glycemic control and body weight by increasing insulin production and release in a glucose-dependent manner; decreasing glucagon secretion ...